A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance

TY - JOUR

T1 - A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance

AU - Howes, O D

AU - Bhatnagar, A

AU - Gaughran, F P

AU - Amiel, S A

AU - Murray, R M

AU - Pilowsky, L S

PY - 2004/2

Y1 - 2004/2

N2 - Objective: This prospective study examines the effect of clozapine on glucose control and insulin sensitivity. Method: Glucose homeostasis was measured in nine female and 11 male patients with schizophrenia (mean age = 30.5 years, SD = 7.4) before clozapine treatment and after a mean of 2.5 months (SD = 0.95) of clozapine treatment. Oral glucose tolerance and insulin levels were measured. insulin resistance level was measured by the homeostasis model assessment. Results: Eleven (55%) of the patients developed abnormal glucose control; the mean age of these patients was 30.2 (SD = 7.1), and five were women. Patients' insulin resistance at baseline (mean insulin resistance level = -3.88, SD = 2.93) was unaffected by clozapine. Mean fasting and 2-hour glucose levels significantly increased by 0.55 mmol/liter and 1.4 mmol/liter, respectively. There was no correlation between change in body mass index and change in fasting glucose levels. Conclusions: Clozapine impairs glucose control within 4 months of treatment, independent of changes in insulin sensitivity and body mass index.

AB - Objective: This prospective study examines the effect of clozapine on glucose control and insulin sensitivity. Method: Glucose homeostasis was measured in nine female and 11 male patients with schizophrenia (mean age = 30.5 years, SD = 7.4) before clozapine treatment and after a mean of 2.5 months (SD = 0.95) of clozapine treatment. Oral glucose tolerance and insulin levels were measured. insulin resistance level was measured by the homeostasis model assessment. Results: Eleven (55%) of the patients developed abnormal glucose control; the mean age of these patients was 30.2 (SD = 7.1), and five were women. Patients' insulin resistance at baseline (mean insulin resistance level = -3.88, SD = 2.93) was unaffected by clozapine. Mean fasting and 2-hour glucose levels significantly increased by 0.55 mmol/liter and 1.4 mmol/liter, respectively. There was no correlation between change in body mass index and change in fasting glucose levels. Conclusions: Clozapine impairs glucose control within 4 months of treatment, independent of changes in insulin sensitivity and body mass index.

U2 - 10.1176/appi.ajp.161.2.361

DO - 10.1176/appi.ajp.161.2.361

M3 - Article

SN - 1535-7228

VL - 161

SP - 361

EP - 363

JO - The American Journal of Psychiatry

JF - The American Journal of Psychiatry

IS - 2

ER -